August 25, 2015


FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung

  • Regulatory submissions are based on positive data from LUX-Lung 8 study that showed a significant delay in progression of lung cancer (progression-free survival, primary endpoint) and a significant improvement in overall survival for Giotrif® (afatinib*) compared to Tarceva® (erlotinib)
  • LUX-Lung 8 is a large, prospective Phase III head-to-head trial which compared two EGFR-directed treatments in patients with squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy
  • Afatinib has also been granted orphan drug designation...

    Continue Reading >

August 24, 2015


Keep the glowing holiday skin the entire year with Bio-Oil

Getting back from the holidays is never easy, and getting into the routine is even harder. One way of ensuring your spirits are exactly like they were during the holidays is looking like you did on that long cruise or in the by lanes of a forgotten city or simply in your home reading a book and sipping on aromatic tea. Bio-Oil, the wonder skin care formula will help you feel gorgeous long after the holiday season has worn off.


Continue Reading >

August 22, 2015


Prime Minister inaugurates Athena Medical Center in Constantine

Prime Minister Abdelmalek Sellal inaugurated Thursday, as part of an inspection and working visit to Constantine (431-km east of Algiers), a private cancer hospital, namely Athena Medical Center, and a stele marking the fiftieth anniversary of Algeria's independence (1962).

At Athena Medical Center, Sellal visited the various departments, stressing that "the private"...

Continue Reading >

August 20, 2015


Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. EMPA-REG OUTCOME® met its primary endpoint and demonstrated superiority of Jardiance®, when added to standard of care, in CV risk reduction. The primary endpoint was defined as time to first occurrence of either"...

Continue Reading >

August 17, 2015


New data show Spiolto Respimat provides meaningful quality of life improvements in COPD

  • OTEMTO® trials show Spiolto® Respimat® provides clinically meaningful >4 point reduction in SGRQ score compared to placebo1
  • These results demonstrate that Spiolto® Respimat® can bring noticeable benefits to the daily life of COPD patients

Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/...

Continue Reading >

August 12, 2015


Equipo Announces 23 New Cycling Tour Dates to Colombia

(ME NewsWire)-- Equipo announces 2015-2016 dates for cycling holidays to Colombia, including Boyacá, Nairo Quintana’s home region and training ground for the Tour de France.

This Smart News Release features multimedia. View the full release here:


Continue Reading >

August 8, 2015


Algerian system of access to healthcare is model (UNFPA)

The Algerian system of access to care and the free services provided constitutes a "model" on Thursday stressed Regional Director General of the Arab States of UNFPA (United Nations Population Fund), Mohamed Abdel Ahad, said a statement from the Ministry of Health, Population and Hospital Reform.

"The Algerian system and access to free care is a model," he said during"...

Continue Reading >

August 3, 2015


PENTAX Europe GmbH Appoints Rainer Burkard President of Europe, Middle East and Africa Region (EMEA)

(ME NewsWire)-- PENTAX Europe GmbH, a division of HOYA Corporation, announced the appointment of Mr. Rainer Burkard to the position of President Europe, Middle East and Africa (EMEA) as of 1st August 2015. In this executive role, Rainer Burkard is responsible for leading all PENTAX Medical activities in the EMEA region.

“Rainer joins PENTAX Medical with valuable expertise gained from various segments of"...

Continue Reading >

July 28, 2015


Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

  • Boehringer Ingelheim expands its strong position in lung cancer obtaining exclusive rights to HM61713, a 3rd generation EGFR targeting agent
  • This new partnership will aim to achieve first market authorisation for HM61713 for patients with EGFR mutation-positive NSCLC by 2017 in the U.S.
  • Expands Boehringer Ingelheim’s broad commitment to cancer and specifically the development of innovative targeted therapies in lung cancer

Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today"...

Continue Reading >

July 28, 2015


cippe 2015 Shanghai: Focus on Innovation and Upgrade of Global Petrochemical Industry and Market Trends

In the coming five years, China's economy will see significant changes in many aspects, with the economic growth rate from high to moderate, the growth pattern from extensive growth in scale and speed to intensive growth in quality and efficiency, its driving force from investment to innovation, and the structure from capacity expansion-oriented to expansion-and-optimization-oriented. Focusing on the upgrade of the traditional petrochemical industry, the challenges faced by the industry and the development trends of the petrochemical"...

Continue Reading >

Forex Market Video